加载中
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
前收盘价
US$8.84
+US$0.23 · +2.67%
盘前
US$9.10
+US$0.26 · +2.94%
10月12日 7:19 ET
盘中时间采用ET。市场数据可能有所延迟。
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
日内区间
当前US$8.84
52周区间
当前US$8.84
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
47
合理估值
情绪
54
多空交织
风险
47
风险偏高
动量
37
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
日内区间
当前US$8.84
52周区间
当前US$8.84
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 968.4万 USD | 1.35亿 USD | 9137万 USD | 5390.5万 USD | 2.01亿 USD |
| 销货成本 | 370.2万 USD | — | — | — | — |
| 毛利 | 598.2万 USD | 1.35亿 USD | 9137万 USD | 5390.5万 USD | 2.01亿 USD |
| 研究与开发 | 1.35亿 USD | 2.23亿 USD | 2.21亿 USD | 1.36亿 USD | 8228.4万 USD |
| 销售、一般及管理费用 | 5939.2万 USD | 6719.9万 USD | 6183.5万 USD | 4990万 USD | 4631.8万 USD |
| 营业费用 | 1.91亿 USD | 2.9亿 USD | 2.82亿 USD | 1.85亿 USD | 1.29亿 USD |
| 利息收入 | 1413.9万 USD | 2581.6万 USD | 3101.4万 USD | 634.9万 USD | 4.2万 USD |
| 折旧和摊销 | 89.5万 USD | 89.3万 USD | 92.8万 USD | 74.4万 USD | 111.5万 USD |
| 营业利润 | −1.85亿 USD | −1.55亿 USD | −1.91亿 USD | −1.32亿 USD | 7197.5万 USD |
| 净利润 | −2.44亿 USD | −1.22亿 USD | −1.47亿 USD | −1.17亿 USD | 6697.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$30.00
上涨空间 239.37%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM980.75万0.01%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI789.02万0.08%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF458.34万0.00%954亿 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS316.97万0.01%338.69亿 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB299.3万0.03%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO238.57万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO201.2万0.01%139.17亿 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA184.88万0.01%218.24亿 USD0.03%US$32.79+0.40%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
